

Special Issue

Recent Research on Esophageal Cancer

Message from the Guest Editor

Esophageal cancer is the seventh most common cancer worldwide, and endoscopic treatment during the early stages is associated with promising outcomes. Neoadjuvant chemotherapy or chemoradiotherapy combined with surgery is the standard treatment for advanced-stage cancer. In addition to surgery, chemoradiotherapy is also a useful radical therapeutic option, particularly for patients with inoperable cancer. Although chemoradiotherapy is more effective than radiotherapy alone, exclusive radiotherapy is preferred as a radical treatment for patients in poor general condition. The Special Issue will highlight treatment perspectives for esophageal cancer, including investigations focused on various aspects such as basic, clinical, and economic research.

Guest Editor

Dr. Takashi Ono
QST hospital, Chiba, Japan

Deadline for manuscript submissions

closed (30 June 2021)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/55274

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)